Thông tin cho nhân viên y tế
Thuốc mới và thông tin từ Drugs.com
- BURLINGTON, Mass.–(BUSINESS WIRE)–August 31, 2026 PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446) today announced the U.S. Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon…
- OSAKA, Japan and CAMBRIDGE, Massachusetts, August 28, 2026 – Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for Mimrylo (rusfertide) for the treatment of erythrocytosis…
- FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR)…
- August 28, 2026 — The U.S. Food and Drug Administration has approved Stelara (ustekinumab) injection for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients aged 2 years old and older. On April 15, 2026…
- INDIANAPOLIS, August 28, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of…
- CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2026-2027 formulas for…
- WEDNESDAY, Sept. 2, 2026 — Time-restricted eating (TRE) may help adults with type 1 diabetes (T1D) and overweight control their blood sugar, according to a study published online Aug. 17 in Diabetes Care.Mary-Claire Runchey, R.D., from the…
- WEDNESDAY, Sept. 2, 2026 — Residential context has a stronger association with survival for Black than White women with epithelial ovarian cancer (EOC), according to a study published online Aug. 10 in JAMA Network Open.Francesmary Modugno, Ph.D…
- WEDNESDAY, Sept. 2, 2026 — For community-dwelling older adults without clinical cardiovascular disease, atorvastatin is associated with a lower risk for major cardiovascular events, but does not improve disability-free survival, according to a…
- WEDNESDAY, Sept. 2, 2026 — Updated recommendations are presented for the use of radiation therapy (RT) in pancreatic cancer in a clinical practice guideline issued by the American Society for Radiation Oncology and published online Aug. 11 in…
- WEDNESDAY, Sept. 2, 2026 — For women with autoimmune disease who had received autologous CD19-chimeric antigen receptor (CAR) T-cell therapy, pregnancies seem to be uncomplicated without disease reactivation, according to a study published in the…
- WEDNESDAY, Sept. 2, 2026 — Updated recommendations are presented to help clinicians decide which medications may be effective for preventing migraine in adults in two reports issued by the American Academy of Neurology and American Headache Society…
Thông tin từ The Pharma Letter
- Priothera, a late-stage clinical biopharmaceutical company, has announced the appointment of Dr Nigel Clark, as chief business officer (CBO).
- Italian biotech Resalis Therapeutics has appointed Diana Røpcke as chief medical officer (CMO).
- Shares of Chinese biopharma Hutchmed leapt 15.3% to HK$22.06 after it announced an exclusive development and license agreement with a subsidiary of GSK, granting worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830.
- Franco-American AI firm Owkin has signed a licensing agreement with Boehringer Ingelheim.
- South Korean biotech Alteogen revealed it has entered into an option and license agreement with Swiss pharma giant Novartis for the development and commercialization of subcutaneous (SC) products utilizing ALT-B4 powered by Alteogen's Hybrozyme technology.
- Japanese pharma major Eisai and US biotech Biogen said China's National Medical Products Administration (NMPA) has approved the subcutaneous autoinjector formulation of Leqembi (lecanemab) as an initiation treatment for mild cognitive impairment or mild dementia due to Alzheimer's disease, collectively termed early Alzheimer's disease.
Thông tin từ BioPharmaDive
- CAR-T’s commercial challenge is making thousands of patient-specific manufacturing runs behave like one reliable system. "In vivo" production techniques could be one solution.
- Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.
- The company is now hoping for an affirmative answer on its application after an unusually turbulent year dealing with U.S. regulators.
- Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.
- Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.
- Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.
Thông tin từ STAT News
- Anthony Fauci is working on a book, we unpack Trump's latest drug pricing deals, and more from STAT's D.C. Diagnosis newsletter.
- Drug overdose deaths decreasing, a path to patients for AI devices, and more health news from Morning Rounds
- In this edition of STAT Health Tech: What FDA's TEMPO pilot means for AI regulation, OpenEvidence launches new AI models, and more.
- The latest pharma news from the Pharmalot campus via the Pharmalittle newsletter
- Biotech M&A activity is off the charts, yet the French drugmaker Abivax hasn't been picked up yet. There may be some explanations.
- At a "practice of last resort," pediatricians prioritize allaying parents' vaccine concerns without hardline dismissals.
Thông tin từ Nature Review Drug Discovery
- Nature Reviews Drug Discovery, Published online: 02 September 2026; doi:10.1038/d41573-026-00146-xClick chemistry platform enhances ADC tumour targeting
- Nature Reviews Drug Discovery, Published online: 01 September 2026; doi:10.1038/s41573-026-01513-4Solute carrier transporters are critical for maintaining central nervous system homeostasis, and their dysregulation is implicated in neurological diseases. This Review discusses the roles of solute carriers in neurodegenerative diseases, autism spectrum disorders and epilepsy, highlighting therapeutic strategies to modulate their activity, emerging technologies and tools […]
- Nature Reviews Drug Discovery, Published online: 28 August 2026; doi:10.1038/d41573-026-00140-3The landscape for in vivo CAR T cell therapies
- Nature Reviews Drug Discovery, Published online: 28 August 2026; doi:10.1038/d41573-026-00142-1CAR-T cell therapy for multiple sclerosis
- Nature Reviews Drug Discovery, Published online: 28 August 2026; doi:10.1038/d41573-026-00144-zSerotonin receptor agonist suppresses colorectal cancer
- Nature Reviews Drug Discovery, Published online: 28 August 2026; doi:10.1038/d41573-026-00141-2Viral protease-initiated pyroptosis